{"filing":{"accession_number":"0000917520-26-000055","cik":"0000917520","ticker":"IART","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"iart-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752026000055/iart-20260729.htm"},"events":[{"id":21319,"run_id":19224,"accession_number":"0000917520-26-000055","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Q2 2026 financial results for Integra LifeSciences. The Item 2.02 filing explicitly states \"Integra LifeSciences Holdings Corporation (the 'Company') issued a press release announcing financial results for the quarter ended June 30, 2026\" and includes detailed quarterly revenue ($418.8M), GAAP earnings per diluted share ($0.06), adjusted EPS ($0.56), and full-year guidance. The attached press release (Exhibit 99.1) is a standard earnings announcement with segment performance, balance sheet metrics, and forward guidance.","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":20937,"accession_number":"0000917520-26-000055","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Integra LifeSciences. The Item 2.02 filing explicitly states \"Integra LifeSciences Holdings Corporation (the 'Company') issued a press release announcing financial results for the quarter ended June 30, 2026\" and includes detailed quarterly revenue ($418.8M), GAAP earnings per diluted share ($0.06), adjusted EPS ($0.56), and full-year guidance. The attached press release (Exhibit 99.1) is a standard earnings announcement with segment performance, balance sheet metrics, and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:16:43.530483+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20937,"accession_number":"0000917520-26-000055","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Q2 2026 financial results for Integra LifeSciences. The Item 2.02 filing explicitly states \"Integra LifeSciences Holdings Corporation (the 'Company') issued a press release announcing financial results for the quarter ended June 30, 2026\" and includes detailed quarterly revenue ($418.8M), GAAP earnings per diluted share ($0.06), adjusted EPS ($0.56), and full-year guidance. The attached press release (Exhibit 99.1) is a standard earnings announcement with segment performance, balance sheet metrics, and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:16:43.530483+00:00","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","ticker":"IART","filing_date":"2026-07-29"}]}